Open AccessNeutrophil–Lymphocyte Ratio Connected to Treatment Options and Inflammation Markers of Ankylosing Spondylitis
Author(s) -
Gökmen Ferhat,
Akbal Ayla,
Reşorlu Hatice,
Gökmen Esra,
Güven Mustafa,
Aras Adem Bozkurt,
Erbağ Gökhan,
Kömürcü Erkam,
Akbal Erdem,
Coşar Murat
Publication year - 2015
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.21768
Subject(s) - ankylosing spondylitis , medicine , erythrocyte sedimentation rate , neutrophil to lymphocyte ratio , gastroenterology , white blood cell , c reactive protein , inflammation , acute phase protein , lymphocyte , spondylitis , absolute neutrophil count , immunology , chemotherapy , neutropenia
Background In recent years, white blood cells (WBCs) and their subtypes have been studied in relation to inflammation. The aim of our study was to assess the relationship between neutrophil–lymphocyte ratio (NLR) and ankylosing spondylitis (AS). Materials and methods We enrolled a total of 177 patients, 96 AS and 81 healthy controls. Complete blood count, WBC, neutrophil and lymphocyte levels were measured, and the NLR was calculated. In the assessment of AS, we used the erythrocyte sedimentation rate, C‐reactive protein (CRP), the Bath Ankylosing Spondylitis Disease Activity Index, and the Bath Ankylosing Spondylitis Functional Index. Results In the present study, 96 AS and 81 healthy individuals were enrolled. The mean age was 43.8 ± 12.9 and 46.5 ± 11.2 years, respectively. Mean disease duration of AS patients was 6.9 ± 5.6 years (median = 5, min–max = 1–25). The patients with AS had a higher NLR than the control individuals (mean NLR, 2.24 ± 1.23 and 1.73 ± 0.70, respectively, P < 0.001). A statistically significant positive correlation was observed between NLR and CRP ( r = 0.322, P = 0.01). The patients receiving antitumor necrosis factor α therapy had a lower NLR than the patients receiving nonsteroidal anti‐inflammatory drug therapy (mean NLR, 1.71 ± 0.62 and 2.41 ± 1.33, respectively, P = 0.02). Conclusion NLR may be seen as a useful marker for demonstrating inflammation together with acute phase reactants such as CRP and in evaluating the effectiveness of anti‐TNF‐α therapy.